Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow-Up

被引:0
作者
Riggott, Christy [1 ,2 ]
Fairbrass, Keeley M. [1 ,2 ]
Gracie, David J. [1 ,2 ]
Ford, Alexander C. [1 ,2 ]
机构
[1] St James Univ Hosp, Leeds Gastroenterol Inst, Leeds, England
[2] Univ Leeds, Leeds Inst Med Res St Jamess, Leeds, England
关键词
gut-brain axis; healthcare utilisation; inflammatory bowel disease; prognosis; psychological health; psychology; QUALITY-OF-LIFE; ULCERATIVE-COLITIS; CROHNS-DISEASE; DEPRESSION; ANXIETY; STRESS; SYMPTOMS; PREVALENCE; RELAPSE; NEUROMODULATORS;
D O I
10.1111/apt.70086
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Common mental disorders, including anxiety and depression, are prevalent in patients with inflammatory bowel disease (IBD) and may be associated with adverse outcomes. However, whether increasing psychological co-morbidity, in combination with disease activity, exerts a cumulative effect on prognosis is uncertain. Aims To assess this in a longitudinal follow-up study. Methods We collected baseline demographic and IBD-related information, clinical activity using disease activity scores and biochemical activity using calprotectin. Patients were grouped according to the presence or absence of disease activity. Patients in remission or with active disease were subgrouped according to the presence or absence of symptoms of a common mental disorder at baseline. We recorded the occurrence of adverse outcomes over 8.1 years, comparing their occurrence across subgroups using Cox regression. Results Among 717 participants with clinical activity data and 187 with clinical and biochemical activity data, rates of adverse outcomes increased with both disease activity and increasing psychological co-morbidity. Rates of flare or glucocorticosteroid prescription, escalation or death were higher with clinical activity (HR 2.89; 95% CI 1.68-4.93 and 2.52; 95% CI 1.55-4.10 and 6.97; 95% CI 2.43-20.0, respectively) or clinical and biochemical activity (HR 7.26; 95% CI 2.86-18.5, 3.62; 95% CI 1.59-8.25 and 57.3; 95% CI 7.58-433, respectively) and two common mental disorders. Rates of hospitalisation (HR 6.20; 95% CI 1.88-20.4) or hospitalisation and/or intestinal resection (HR 7.46; 95% CI 2.41-23.2) were higher with clinical and biochemical activity and two common mental disorders. Conclusion Psychological co-morbidity and active disease have a cumulative adverse impact on IBD prognosis.
引用
收藏
页码:1635 / 1648
页数:14
相关论文
共 50 条
[1]   Relative Contribution of Disease Activity and Psychological Health to Prognosis of Inflammatory Bowel Disease During 6.5 Years of Longitudinal Follow-Up [J].
Fairbrass, Keeley M. ;
Gracie, David J. ;
Ford, Alexander C. .
GASTROENTEROLOGY, 2022, 163 (01) :190-+
[2]   Impact of Opioid Use on the Natural History of Inflammatory Bowel Disease: Prospective Longitudinal Follow-up Study [J].
Riggott, Christy ;
Fairbrass, Keeley M. ;
Selinger, Christian P. ;
Gracie, David J. ;
Ford, Alexander C. .
INFLAMMATORY BOWEL DISEASES, 2023, 30 (10) :1724-1731
[3]   Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 12 months of longitudinal follow-up [J].
Barberio, Brigida ;
Fairbrass, Keeley M. ;
Gracie, David J. ;
Ford, Alexander C. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2024, 36 (02)
[4]   Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up [J].
Fairbrass, Keeley M. ;
Hamlin, P. John ;
Gracie, David J. ;
Ford, Alexander C. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (08) :1264-1273
[5]   Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease [J].
Fairbrass, Keeley M. ;
Gracie, David J. ;
Ford, Alexander C. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (04) :441-450
[6]   Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study [J].
Riggott, Christy ;
Fairbrass, Keeley M. ;
Black, Christopher J. ;
Gracie, David J. ;
Ford, Alexander C. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (11-12) :1163-1174
[7]   Impact of Sleep Quality on Disease Activity and Clinical Outcomes in Older Patients with Inflammatory Bowel Disease [J].
Cavusoglu, Cagatay ;
Sahin, Tevhide ;
Bas, Arzu Okyar ;
Guner, Merve ;
Boga, Ilker ;
Ozturk, Yelda ;
Keskin, Onur ;
Parlak, Erkan ;
Sivri, Bulent ;
Halil, Meltem Gulhan ;
Cankurtaran, Mustafa ;
Kav, Taylan ;
Dogu, Burcu Balam .
EUROPEAN JOURNAL OF GERIATRICS AND GERONTOLOGY, 2024, 6 (03) :178-184
[8]   Poor sleep quality is common and independently associated with disease activity and poor quality of life in inflammatory bowel disease: a long-term follow-up study [J].
Chaemsupaphan, Thanaboon ;
Pimolsri, Chawanont ;
Subdee, Nichcha ;
Phaophu, Phutthaphorn ;
Salaemae, Marianee ;
Permpim, Parinya ;
Thongchot, Lakkana ;
Wannasewok, Kamonnet ;
Chotinaiwattarakul, Wattanachai ;
Limsrivilai, Julajak .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18
[9]   Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease [J].
Gracie, David J. ;
Hamlin, P. John ;
Ford, Alexander C. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (05) :702-712
[10]   Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study [J].
Goodoory, Vivek C. ;
Houghton, Lesley A. ;
Yiannakou, Yan ;
Black, Christopher J. ;
Ford, Alexander C. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (03) :569-+